Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVP: EDP-938 in Adult RSV URTI
NCT04196101Phase 2Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing EDP-938 with Placebo (2 arms). Primary endpoint: Total Symptom Score Area Under the Curve. Started Jan 2020; status: completed.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04196101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04196101.